Wan Mohamed Wan Bebakar

Liraglutide, a once‐daily human GLP‐1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD‐1 SU)

Michel Marre, J. Shaw, Michael Brändle et al. · Diabetic Medicine · 2009 · 815 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT

Krzysztof Strojek, Wan Mohamed Wan Bebakar, Duma Khutsoane et al. · Current Medical Research and Opinion · 2009 · 83 citations

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy and safety of liraglutide compared to sulphonylurea during <scp>R</scp> amadan in patients with type 2 diabetes ( <scp>LIRA‐R</scp> amadan): a randomized trial

Sami T. Azar, Akram Echtay, Wan Mohamed Wan Bebakar et al. · Diabetes Obesity and Metabolism · 2016 · 49 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Prevalence of aspirin resistance in diabetic patients and its associated factors.

Nor Halwani Habizal, Sanihah Abdul Halim, Shalini Bhaskar et al. · PubMed · 2015 · 11 citations

Medicine, Internal Medicine, Pharmacology +13